Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C

Completed · Not applicable

Conditions studied: Hepatitis C, Cirrhosis, Fibrosis

In brief

The primary purpose of this study is to determine if peginterferon alpha-2a maintenance therapy (90 mcg/week) will lower portal pressure in patients with hepatitis C virus infections and advanced fibrosis or cirrhosis.

Key facts

Study ID

NCT00252642

Run by

Virginia Commonwealth University

People needed

60

Starts

2005-11-01

Expected to finish

2007-09-01

Last updated by the study team

2017-03-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Completion of HALT-C Trial, in either treatment or non-treatment arm

You may not qualify if…

• Non-completion of HALT-C Trial
• Patients who do not wish to be treated with peginterferon after the first portal pressure measurement
• Hepatocellular Carcinoma
• Underlying autoimmune disorder
• Currently being treated with immune suppressive agent
• Illicit drug use
• Alcohol use of more than 6 grams per day
• Advanced cardiopulmonary disease
• Uncontrolled diabetes mellitus
• Patients who, in the opinion of the investigator, should not participate in this trial

Where it is running

• Virginia Commonwealth University — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.